JAPAN
Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.
Contribution to Group revenue (%)

Revenue by segment (%)

- The Japanese pharmaceutical sector continues to be negatively impacted by regulated price revisions and was valued at USD76 billion as at 31 December 2018
Source: December 2018 IQVIA
STATISTICS
Number of products launched:
4
(2018: 9)#
In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
Nil
3 – 5 years
Nil
Number of product recalls:
Nil
(2018: Nil)
Average staff turnover:
13,9%
(2018: 12,8%)
Number of work-related fatalities:
Nil
(2018: Nil)
Number of permanent employees:

# The number of product launches has been restated to take into account discontinued operations.
Revenue | 2019 R'million | 2018 (CER) R'million | change % |
---|---|---|---|
Regional Brands | 760 | 735 | 3 |
Sterile Focus Brands | 1 364 | 1 384 | (1) |
Anaesthetics Brands | 1 332 | 1 331 | 0 |
Thrombosis Brands | 32 | 53 | (40) |
Total | 2 124 | 2 119 | 0 |
Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.